Escitalopram for Hot Flashes: Four Trial and Prescribing Findings

If a clinician suggests an antidepressant for hot flashes, the useful questions are how much benefit to expect, what was measured and which adverse effects would change the decision.

The larger trial counted improvement, not disappearance

The 2011 MsFLASH trial¹ randomized 205 women aged 40–62: 104 to escitalopram and 101 to placebo, for eight weeks. Treatment began at 10 mg daily, with an increase to 20 mg for insufficient improvement at four weeks. This is the research schedule.¹

At eight weeks, 55% versus 36% reported at least a 50% reduction in hot-flash frequency. That threshold did not require complete relief. Participants were generally healthy; current major depression, recent hormone treatment and several serious conditions were excluded. NIH supported the trial; Forest supplied tablets and placebo without a study-design or analysis role.¹

The smaller recorder studies gave a different picture

A separate 2011 report described two small studies with 16 and 26 postmenopausal women, respectively. Each compared escitalopram with placebo over eight weeks, using ambulatory recordings rather than relying solely on diaries. These totals include both treatment groups.²

The first study found no significant effect. In the second, a BMI-adjusted analysis favored treatment, with a 14.4% decline versus a 6.7% increase in recorded flash frequency, but raw-frequency and time analyses were not significant. The authors judged clinical usefulness limited and acknowledged small samples. NIH funded the work; the lead author disclosed a patent and ownership of the recorder manufacturer.²

Different measurements complicate comparisons. A recorder result does not invalidate a woman’s account of improvement.¹²

Guidance supports selected antidepressants as nonhormone options

The Menopause Society’s³ 2023 position statement recommends SSRIs and SNRIs for vasomotor symptoms, citing mild-to-moderate improvements. It specifically includes escitalopram among medicines with positive larger trials. This does not mean that every antidepressant has the same evidence or that a nonhormone medicine suits every patient.³

Ask which concern is being treated: hot flashes, a diagnosed mood disorder or both. Agree on how each will be assessed instead of assuming one response proves the other has improved.

The interaction and stopping plans belong in the prescription

The US tablet label revised June 2026 lists depression and anxiety indications, not hot flashes. Hot-flash prescribing is therefore off-label. Warnings include serotonin syndrome, low sodium, sexual dysfunction and bleeding risk, including with NSAIDs or anticoagulants. MAO inhibitors and pimozide are contraindicated combinations.⁴

Tell the prescriber about diuretics, bipolar history, other antidepressants and supplements. The label calls for monitoring mood changes in all patients and notes higher low-sodium risk in older people or those taking diuretics. It recommends gradual dose reduction when possible, rather than abrupt stopping; request an individual plan.⁴

Put the outcome in the visit notes

The Visit Brief in My Body Changed. Now What? uses five headings: stage, top three concerns, previous attempts, history and questions. Add the symptom you want reduced and the activity it interrupts, then agree on a review date and whom to contact about adverse effects.

Our low-dose paroxetine guide covers a different SSRI product with a US menopause indication. Its label and dose should not be transferred to escitalopram.